Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Avadel Pharmaceuticals ( (AVDL) ) is now available.
Avadel Pharmaceuticals has announced a favorable court ruling upholding the FDA’s approval of its drug LUMRYZ, a once-at-bedtime treatment for narcolepsy. This decision reinforces LUMRYZ’s clinical superiority over Jazz Pharmaceuticals’ twice-nightly oxybate products, enabling continued market availability and exclusivity for Avadel. LUMRYZ, approved for both adults and pediatric patients, offers a significant advancement in patient care by minimizing sleep disruption, marking a major milestone for Avadel’s commercial growth.
Find detailed analytics on AVDL stock on TipRanks’ Stock Analysis page.
